TIDMAGL
RNS Number : 9014F
Angle PLC
01 November 2018
For immediate release 1 November 2018
ANGLE plc ("the Company")
Appointment of Dr Jan Groen as Non-Executive Director
Brings significant expertise in commercialising cancer
diagnostics
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce the appointment of Dr Jan Groen as
a Non-Executive Director of the Company effective 1 November
2018.
Dr Groen has extensive Board and Executive level experience in
cancer diagnostics. He is currently President and CEO of MDxHealth,
a Euronext listed molecular diagnostic company that develops and
commercialises cancer diagnostic tests to assist physicians in the
detection and treatment of urological and other cancers, a position
he has held since 2010. During his time at MDxHealth, he has helped
to grow revenues from c. US$4 million in 2012 to c. US$41 million
in 2017, with a total cumulative revenue of over US$100 million by
2017, and raised US$80 million in equity financing. He has
established a CLIA service laboratory in the United States, an ISO
service laboratory in Europe and built a team of over 220 staff to
sell and undertake their prostate and other cancer diagnostic
tests.
Prior to MDx Health, Dr Groen was President of US Operations and
Global Chief Operating Officer at Agendia, a world leader in the
rapidly evolving field of cancer molecular diagnostics using tumor
gene expression, including tests that predict the risk of breast
cancer recurrence (MammaPrint) and to identify the origin of cancer
of unknown primary.
Dr Groen has significant expertise in new product development,
including development of more than 25 CE marked and FDA cleared
diagnostic products and lab-developed tests in Europe and the USA,
and has successfully launched and commercialised several such
tests.
Dr Groen also holds a Non-Executive Board position at SPL
Medical, a private Dutch company combining an innovative contrast
agent (Combidex(R)) with magnetic resonance imaging (MRI), with the
ability to detect small lymph node metastases. He was previously a
board member of MyCartis, a private Belgium company developing a
Dynamic Multi-Analyte Technology (DMAT(R)) for immuno-diagnostics
and IBL International, a VC backed company based in Germany
manufacturing and selling immune-diagnostic assay which was sold to
Tecan in July 2014.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"I am delighted to welcome Jan Groen to the Board of ANGLE. He
has a proven track record of successfully commercialising cancer
diagnostics in the USA and Europe. His knowledge and experience of
this market will be of significant value as we progress the
commercialisation of our Parsortix(TM) liquid biopsy solution."
The following information regarding Jan Groen, aged 58, is
disclosed under Schedule 2(g) of the AIM Rules for Companies:
Current directorships and/or partnerships Former directorships and/or partnerships
(within the last five years)
MDxHealth S.A. MyCartis NV
SPL Medical B.V. IBL International
DxOrange B.V.
There are no further disclosures to be made under Schedule 2g of
the AIM Rules for Companies.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark in
Europe for the indicated use and FDA clearance is in process for
the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for low cost, highly
multiplexed, rapid and sensitive capture of targets from a wide
variety of sample types. A proprietary chemistry approach allows
for the capture and amplification of over 100 biomarkers
simultaneously in a single reaction. The Ziplex system is ideal for
measuring gene expression and other markers directly from Parsortix
harvests.
ANGLE's proprietary technologies can be combined to provide
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats.
Furthermore, ANGLE has established formal collaborations with
world-class cancer centres. These Key Opinion Leaders are working
to identify applications with medical utility (clear benefit to
patients), and to secure clinical data that demonstrates that
utility in patient studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFDAFDFFASEES
(END) Dow Jones Newswires
November 01, 2018 03:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024